Efficacy and Safety of Vutrisiran in Transthyretin Amyloid Cardiomyopathy Across the Age Spectrum: The HELIOS-B Trial
Vutrisiran reduced all-cause mortality and cardiovascular events and maintained function and quality of life in patients with ATTR-CM across the age spectrum, including those ≥80 years.
Authors
- Awais Sheikh (ORCID: https://orcid.org/0000-0002-7707-226X)
- Emre Aldinc (ORCID: https://orcid.org/0000-0002-7237-4760)
- Brian Claggett
- Julian D. Gillmore (ORCID: https://orcid.org/0000-0001-6174-9232)
- Pablo García‐Pavía (ORCID: https://orcid.org/0000-0002-5470-2257)
- Francesco Cappelli (ORCID: https://orcid.org/0000-0002-1622-0732)
- Zi Michael Miao (ORCID: https://orcid.org/0000-0002-2377-1444)
- Scott Solomon
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Alnylam Pharmaceuticals (United States) (US)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Amyloidosis Foundation (US)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University College London (GB)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1002/ejhf.70084
- Citations
- 1
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals
- European Society of Cardiology
- Novo Nordisk